MULTIPLE-MYELOMA RESISTANT TO MELPHALAN - TREATMENT WITH DOXORUBICIN, CYCLOPHOSPHAMIDE, CARMUSTINE (BCNU), AND PREDNISONE
- 1 January 1982
- journal article
- research article
- Vol. 66 (3), 451-456
Abstract
Sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide, doxorubicin (adriamycin) and prednisone (CAP) (30 patients) or carmustine (BCNU), doxorubicin and prednisone (BAP) (35 patients). Objective responses occurred in 2 patients in the CAP group and 7 in the BAP group. Indirect responses were noted in 7 additional patients in the CAP group and in 6 additional patients in the BAP group. Toxic effects consisted mainly of leukopenia and thrombocytopenia. Median survival did not differ between the 2 treatment groups (CAP, 8.4 mo.; BAP, 7.7 mo.). Objective responders had a longer survival than nonresponders (14.5 mo. vs. 7.7 mo.).This publication has 8 references indexed in Scilit:
- MULTIPLE-MYELOMA RESISTANT TO MELPHALAN - TREATMENT WITH CYCLOPHOSPHAMIDE, PREDNISONE, AND BCNU1979
- Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962), cyclophosphamide plus prednisone (ABC-P) in melphalan-resistant multiple myelomaCancer, 1978
- PHASE-II STUDY OF ADRIAMYCIN AND BLEOMYCIN IN PATIENTS WITH MULTIPLE-MYELOMA1978
- DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSEThe Lancet, 1976
- Melphalan and MyelomaAnnals of Internal Medicine, 1970
- Melphalan in Multiple MyelomaBlood, 1967
- MULTIPLE MYELOMA - .2. ANALYSIS OF CYCLOPHOSPHAMIDE THERAPY IN 165 PATIENTS1964
- EVALUATION OF NEW CHEMOTHERAPEUTIC AGENTS IN THE TREATMENT OF MULTIPLE MYELOMA .4. L-PHENYLALANINE MUSTARD (NSC-8806)1962